(Q53245194)

12 May 2018

title

Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease. (English)

1 reference

12 May 2018

author name string

Carol A. Scorer

series ordinal

1

1 reference

12 May 2018

publication date

1 December 2001

1 reference

12 May 2018

published in

Drug Discovery Today

1 reference

12 May 2018

volume

6

1 reference

12 May 2018

issue

23

1 reference

12 May 2018

page(s)

1207-1219

1 reference

12 May 2018

The US economic and social costs of Alzheimer's disease revisited

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Amyloid beta-protein and the genetics of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Molecular genetics of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

The molecular genetics of the tauopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Alzheimer's disease: the amyloid cascade hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Purification and cloning of amyloid precursor protein beta-secretase from human brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

BACE1 is the major beta-secretase for generation of Abeta peptides by neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Expression analysis of BACE2 in brain and peripheral tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Presenilin function in APP processing

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

The type 4 prepilin peptidases comprise a novel family of aspartic acid proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Gamma -secretase inhibitors repress thymocyte development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

The neurotoxic carboxy-terminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: pH dependence of the neurotoxicity and the binding

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Abeta modulation: the next generation of AD therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Alzheimer's disease. The tangled tale of tau.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Alzheimer's disease: an inflammatory disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Causes or consequences of inflammation and pathological signs of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Glial-derived proteins activate cultured astrocytes and enhance beta amyloid-induced glial activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?: The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Risk of Alzheimer's disease and duration of NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

NSAIDs and incident Alzheimer’s disease. the Rotterdam study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Inflammation of the brain in Alzheimer's disease: implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Apoptosis and neurologic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Apoptosis in the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

The neurotoxicity of amyloid beta protein in aged primates.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

From bench to clinic with apoptosis-based therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Statins and the risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Gene expression profile of aging and its retardation by caloric restriction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Gene-expression profile of the ageing brain in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Mitotic misregulation and human aging

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Recent work on Alzheimer's disease transgenics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Progress toward valid transgenic mouse models for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Transgenic mouse models of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Neuron loss in APP transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Single and multiple transgenic mice as models for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Quantitative volumetric analyses of brain magnetic resonance imaging from rat with chronic neuroinflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Clinical trial designs for demonstrating disease-course-altering effects in dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Biomarkers of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Diagnostic approaches to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Pharmacogenetics and the practice of medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Mild cognitive impairment: conceptual basis and current nosological status.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Visualisation and quantification of rates of atrophy in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Correlation between rates of brain atrophy and cognitive decline in AD.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2801%2902042-6

7 January 2021

10.1016/S1359-6446(01)02042-6

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

11722873

1 reference

12 May 2018